The U.S. Food and Drug Administration approved Vyvgart (efgartigimod alfa-fcab) for the treatment of generalized myasthenia gravis (gMG) in adult patients positive for anti-acetylcholine receptor (AChR) antibody.
https://www.pharmalive.com/wp-content/uploads/2021/12/Argenxs-Regulatory-Milestone-Offers-New-Hope-for-gMG-Patients-BioSpace-.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2021-12-20 11:52:362021-12-20 13:20:35FDA approves Vyvgart for treatment of gMG